News Releases

ALPN-101 Progresses to Multiple-Ascending Dose Cohorts of Phase I Study ALPN-202 Submission for Clinical Trial Authorization Anticipated by Year End 2019 SEATTLE --(BUSINESS WIRE)--Aug. 13, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on

SEATTLE --(BUSINESS WIRE)--Aug. 1, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Wedbush

SEATTLE --(BUSINESS WIRE)--Jun. 3, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the appointment of Wayne Gombotz , PhD as Chief

SEATTLE --(BUSINESS WIRE)--May 24, 2019-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in three upcoming

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ: ALPN ), a leading immunotherapy company focused on developing treatments

Alpine transitions to clinical-stage company Completed financing to fund further development of both lead programs SEATTLE --(BUSINESS WIRE)--May 9, 2019-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for

SEATTLE --(BUSINESS WIRE)--Apr. 18, 2019-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN) (“Alpine”), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced Stanford Peng , M.D.

First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 Completed $25 Million Private Placement Strong Financial Position to Transition Two Lead Programs ALPN-101 and ALPN-202 into Patients SEATTLE --(BUSINESS WIRE)--Mar.

SEATTLE --(BUSINESS WIRE)--Feb. 27, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming

Appoints Immunology Veteran Vijay Kuchroo, DVM, PhD to Scientific Advisory Board SEATTLE --(BUSINESS WIRE)--Feb. 19, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and